DOP2001000293A - Kit de repinotano - Google Patents

Kit de repinotano

Info

Publication number
DOP2001000293A
DOP2001000293A DO2001000293A DO2001000293A DOP2001000293A DO P2001000293 A DOP2001000293 A DO P2001000293A DO 2001000293 A DO2001000293 A DO 2001000293A DO 2001000293 A DO2001000293 A DO 2001000293A DO P2001000293 A DOP2001000293 A DO P2001000293A
Authority
DO
Dominican Republic
Prior art keywords
repinothane
kit
repinotane
physiologically harmless
harmless salt
Prior art date
Application number
DO2001000293A
Other languages
English (en)
Inventor
Werner Kroll
Ferdinand Rombout
Klimmen Netherland
Horst Weber
Maria-Luisa Rodriguez
Bernd Sennhenn
Rubolf Schohe-Lood
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of DOP2001000293A publication Critical patent/DOP2001000293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención trata de un kit que incluye una composición farmacéutica, que contiene repinotano o una sal fisiológicamente inofensiva de repinotano, y un medio para determinar la concentración de repinotano o sus metabolitos en liquidos corporales, asi como nuevas composiciones farmaaeuticas, que contienen repinotano o una sal fisiológicamente inofensiva de repinotano, y procedimientos para la preparacion de estos.
DO2001000293A 2000-11-22 2001-11-21 Kit de repinotano DOP2001000293A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10058119A DE10058119A1 (de) 2000-11-22 2000-11-22 Pepinotan-Kit

Publications (1)

Publication Number Publication Date
DOP2001000293A true DOP2001000293A (es) 2002-03-15

Family

ID=7664358

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000293A DOP2001000293A (es) 2000-11-22 2001-11-21 Kit de repinotano

Country Status (37)

Country Link
US (2) US6605255B2 (es)
EP (1) EP1339403B1 (es)
JP (2) JP2004517824A (es)
KR (1) KR20030096237A (es)
CN (2) CN1715279A (es)
AR (1) AR031761A1 (es)
AT (1) ATE284212T1 (es)
AU (1) AU2002227912A1 (es)
BG (1) BG107803A (es)
BR (1) BR0115518A (es)
CA (1) CA2429310A1 (es)
CZ (1) CZ20031401A3 (es)
DE (2) DE10058119A1 (es)
DO (1) DOP2001000293A (es)
EC (1) ECSP034617A (es)
EE (1) EE200300242A (es)
ES (1) ES2234922T3 (es)
GT (1) GT200100236A (es)
HN (1) HN2001000262A (es)
HR (1) HRP20030490A2 (es)
HU (1) HUP0303294A2 (es)
IL (1) IL155975A0 (es)
MA (1) MA26059A1 (es)
MX (1) MXPA03004499A (es)
MY (1) MY118345A (es)
NO (1) NO20032212L (es)
NZ (1) NZ525964A (es)
PE (1) PE20020533A1 (es)
PL (1) PL361628A1 (es)
PT (1) PT1339403E (es)
RU (1) RU2003118583A (es)
SI (1) SI1339403T1 (es)
SK (1) SK5922003A3 (es)
SV (1) SV2003000744A (es)
UY (1) UY27027A1 (es)
WO (1) WO2002041881A2 (es)
ZA (1) ZA200303888B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE19522088A1 (de) * 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19543476A1 (de) * 1995-11-22 1997-05-28 Troponwerke Gmbh & Co Kg Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE19754573A1 (de) * 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
WO1999046591A2 (en) * 1998-03-10 1999-09-16 Strategic Diagnostics, Inc. Integrated assay device and methods of production and use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19936281C2 (de) 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung

Also Published As

Publication number Publication date
HRP20030490A2 (hr) 2005-06-30
CZ20031401A3 (cs) 2003-10-15
JP2005232189A (ja) 2005-09-02
PT1339403E (pt) 2005-03-31
DE10058119A1 (de) 2002-05-23
MA26059A1 (fr) 2004-04-01
WO2002041881A2 (de) 2002-05-30
KR20030096237A (ko) 2003-12-24
JP2004517824A (ja) 2004-06-17
BG107803A (bg) 2004-01-30
EE200300242A (et) 2003-10-15
US20030060493A1 (en) 2003-03-27
EP1339403B1 (de) 2004-12-08
ATE284212T1 (de) 2004-12-15
US6605255B2 (en) 2003-08-12
RU2003118583A (ru) 2004-12-20
AR031761A1 (es) 2003-10-01
UY27027A1 (es) 2002-07-31
NZ525964A (en) 2006-02-24
ECSP034617A (es) 2003-06-25
BR0115518A (pt) 2003-09-16
IL155975A0 (en) 2003-12-23
AU2002227912A1 (en) 2002-06-03
MXPA03004499A (es) 2004-05-14
CN1715279A (zh) 2006-01-04
PL361628A1 (en) 2004-10-04
GT200100236A (es) 2002-06-25
EP1339403A2 (de) 2003-09-03
HN2001000262A (es) 2002-01-30
CN1518446A (zh) 2004-08-04
SI1339403T1 (en) 2005-04-30
HUP0303294A2 (en) 2007-09-28
US20030203953A1 (en) 2003-10-30
MY118345A (en) 2004-10-30
NO20032212D0 (no) 2003-05-15
ES2234922T3 (es) 2005-07-01
SV2003000744A (es) 2003-01-13
CA2429310A1 (en) 2002-05-30
NO20032212L (no) 2003-05-15
DE50104790D1 (de) 2005-01-13
SK5922003A3 (en) 2003-11-04
WO2002041881A3 (de) 2002-10-10
ZA200303888B (en) 2004-05-20
PE20020533A1 (es) 2002-07-13

Similar Documents

Publication Publication Date Title
DOP2001000293A (es) Kit de repinotano
UY28348A1 (es) Compuestos novedosos
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
UY28342A1 (es) Nuevos compuestos
HN2002000154A (es) Azaindoles
CR8257A (es) Construcciones de union y metodos para uso de ellas
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
UY27080A1 (es) Nuevas imidazotriazinonas sustituídas
GT200100132A (es) Derivados de pirazol
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
CR11017A (es) Anticuerpos anti-robo4 y sus usos
PA8684501A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
AR046120A1 (es) Fomulaciones fungicidas que contienen cobre
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
DE60041198D1 (de) Antimikrobielle zusammensetzungen
AR046955A1 (es) Preparacion efervescente de una sustancia basica farmaceuticamente activa
BRPI0413718A (pt) ativadores de plasminogênio tendo uma capacidade reduzida de ligar lisina
ES2169504T3 (es) Composicion farmaceutica solida comprendiendo tiocolchicosido apropiada para la administracion de tiocolchicosido a traves de la mucosa bucal.
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent
ECSP003570A (es) Derivados de 2- bencil-3-dimetilamino-1-fenil- propano